search
Back to results

Effect of Intermittent Calorie Restriction on MASLD Patients With Abnormal Glucose Metabolism

Primary Purpose

Fatty Liver Disease, Type 2 Diabetes, Impaired Glucose Regulation

Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Intermittent calorie restriction (ICR)
Continuous calorie restriction (CCR)
Sponsored by
Shanghai Zhongshan Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Fatty Liver Disease focused on measuring Metabolic dysfunction-associated steatotic liver disease, Type 2 Diabetes

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age 18-70
  2. diagnosed as fatty liver
  3. BMI≥24 kg/m2
  4. The diagnostic criteria for abnormal glucose metabolism are as follows (meeting at least one):

    1. Impaired glucose regulation: fasting blood glucose ≥ 5.6 mmol / L, postprandial blood glucose ≥ 7.8 mmol / L or HbA1c ≥ 5.7%.
    2. Diabetes mellitus: diabetic symptoms + plasma glucose concentration ≥ 11.1 mmol / L at any time or fasting plasma glucose concentration ≥ 7.0 mmol / L or OGTT 2 h plasma glucose concentration ≥ 11.1 mmol / L.

Exclusion Criteria:

  1. Type 1 diabetes, gestational diabetes and other special types of diabetes
  2. Poor blood glucose control, HbA1c > 8.5% within 3 months
  3. Had antidiabetic drugs in the past month
  4. Serum ALT was more than 6 times of normal upper limit
  5. Excessive alcohol consumption (definition: in the past 6 months, alcohol intake: men > 140g, women > 70g)
  6. Other liver diseases: such as acute and chronic viral hepatitis, drug-induced hepatitis, immune hepatitis, liver cirrhosis, liver cancer, etc
  7. Had drugs that may affect NAFLD in the past three months, such as vitamin E
  8. Biliary diseases: biliary obstructive diseases, etc
  9. Other diseases affecting glycolipid metabolism: hyperthyroidism, hypothyroidism, Cushing's syndrome, etc
  10. Chronic kidney disease (serum creatinine ≥ 2.0mg/dl)
  11. Life expectancy of no more than 5 years
  12. Already pregnant or plan to be pregnant in the near future
  13. Mental illness
  14. Other conditions affecting follow-up
  15. Participated in other clinical trials in the past 4 weeks
  16. Absent of informed consent

Sites / Locations

  • Zhongshan Hospital, Fudan University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

Intermittent Calorie Restriction (ICR)

Control (Continuous calorie restriction, CCR)

Arm Description

Participants in ICR group were instructed to ensure 2 successive days of fasting-mimicking and 5 days of recovery per week. On fasting-mimicking days, the participants were instructed to consume approximately 500 kcal/day and they were provided with plant-based meal replacement (ZhenBaiNian nutrition bar, Beijing Wanlaikang Nutrition and Health Food Science and Technology Research Institute Co., Ltd, China) to improve adherence and ensured adequate intake of micronutrients. In the rest 5 days of recovery per week, participants were allowed to consume their usual diet.

Participants in control group were instructed to consume the prescribed calories (25 kcal / kg × [height (cm) - 100] kg) every day by eating conventional food without time restriction.

Outcomes

Primary Outcome Measures

Change of liver fat content in %
Change of liver fat content in %.

Secondary Outcome Measures

Change of weight
Change of weight in kilograms.
Change of blood glucose: fasting blood glucose
Change of fasting blood glucose in mmol/L.
Change of blood glucose: 2h postload blood glucose
Change of 2h postload blood glucose in mmol/L.
Change of HbA1c
Change of HbA1c in %.
Change of liver enzymes: alanine aminotransferase
Change of alanine aminotransferase in U/L.
Change of liver enzymes: aspartate aminotransferase
Change of aspartate aminotransferase in U/L.
Change of liver enzymes: γ-glutamyl transpeptidase
Change of γ-glutamyl transpeptidase in U/L.
Change of lipid profile: total cholesterol
Change of total cholesterol in mmol/L.
Change of lipid profile: triglyceride
Change of triglyceride in mmol/L.
Change of lipid profile: high-density lipoprotein-cholesterol
Change of high-density lipoprotein-cholesterol in mmol/L.
Change of lipid profile: low-density lipoprotein-cholesterol
Change of low-density lipoprotein-cholesterol in mmol/L.
Change of lipid profile: free fatty acid
Change of free fatty acid in mmol/L.

Full Information

First Posted
February 21, 2020
Last Updated
September 24, 2023
Sponsor
Shanghai Zhongshan Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04283942
Brief Title
Effect of Intermittent Calorie Restriction on MASLD Patients With Abnormal Glucose Metabolism
Official Title
Effect of Intermittent Calorie Restriction on Metabolic Dysfunction-Associated Steatotic Liver Disease Patients With Abnormal Glucose Metabolism
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
July 30, 2020 (Actual)
Primary Completion Date
July 25, 2021 (Actual)
Study Completion Date
July 25, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shanghai Zhongshan Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is designed to observe the effect of 5:2 intermittent calorie restriction (fasting 2 days each week) on liver fat content in MASLD patients with abnormal blood glucose.
Detailed Description
Intermittent caloric restriction (ICR) can effectively reduce weight and facilitate blood glucose control, but whether it can be applied for clinical treatment to metabolic dysfunction-associated steatotic liver disease (MASLD) patients remains unclear. We intend to carry out this study in MASLD patients with abnormal glucose metabolism. It is an open-labeled randomized trial designed to observe the effect of 5:2 intermittent calorie restriction (fasting 2 days each week) on liver fat content in MASLD patients with abnormal blood glucose. 60 patients will be randomly divided into ICR group and control group for 12 weeks of intervention. ICR group: during the 2-day fasting-mimicking period each week, the food based on plant ingredients will be served (4 pieces of nutrition bars / day, 1:2:1 for breakfast, lunch and dinner, 124.4kcal / piece, 497.2kcal / day in total). In the rest 5 days each week, subjects are allowed ad libitum to their usual food. Control group (continuous calorie restriction, CCR): under the guidance of nutritionist, subjects have to learn the method of food calories calculation. The daily calories intake for control group should be: 25 kcal / kg × [height (cm) - 100] kg. Daily food diary is required in both groups. During the experiment, all subjects should maintain their exercise routine. The use of drugs affecting blood glucose and fatty liver should be avoided. After 12 weeks of intervention, the changes of liver fat content were evaluated by magnetic resonance spectroscopy (MRS) and Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF). The effects of ICR on body weight, blood glucose and body fat will also be evaluated. Both groups will be followed up on their changes of weight 4 weeks after intervention.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fatty Liver Disease, Type 2 Diabetes, Impaired Glucose Regulation
Keywords
Metabolic dysfunction-associated steatotic liver disease, Type 2 Diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Patients were randomly divided into intermittent calorie restriction group and control group for 12 weeks of intervention. Both groups will be followed up 4 weeks after intervention. ICR group: during the 2-day fasting-mimicking period each week, the food based on plant ingredients will be served (4 pieces of nutrition bars / day, 1:2:1 for breakfast, lunch and dinner, 124.4kcal/piece, 497.2kcal / day in total). In the rest 5 days each week, subjects are allowed ad libitum to their usual food. Control group: continuous calorie restriction (CCR). Under the guidance of nutritionist, subjects have to learn the method of food calories calculation. For each day, the daily calories intake is limited to 25 kcal / kg × standard weight [kg, estimated by height (cm) - 100].
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intermittent Calorie Restriction (ICR)
Arm Type
Experimental
Arm Description
Participants in ICR group were instructed to ensure 2 successive days of fasting-mimicking and 5 days of recovery per week. On fasting-mimicking days, the participants were instructed to consume approximately 500 kcal/day and they were provided with plant-based meal replacement (ZhenBaiNian nutrition bar, Beijing Wanlaikang Nutrition and Health Food Science and Technology Research Institute Co., Ltd, China) to improve adherence and ensured adequate intake of micronutrients. In the rest 5 days of recovery per week, participants were allowed to consume their usual diet.
Arm Title
Control (Continuous calorie restriction, CCR)
Arm Type
Other
Arm Description
Participants in control group were instructed to consume the prescribed calories (25 kcal / kg × [height (cm) - 100] kg) every day by eating conventional food without time restriction.
Intervention Type
Behavioral
Intervention Name(s)
Intermittent calorie restriction (ICR)
Other Intervention Name(s)
Intermittent fasting
Intervention Description
Participants in ICR group were instructed to ensure 2 successive days of fasting-mimicking and 5 days of recovery per week. On fasting-mimicking days, the participants were instructed to consume approximately 500 kcal/day and they were provided with plant-based meal replacement to improve adherence and ensured adequate intake of micronutrients. In the rest 5 days of recovery per week, participants were allowed to consume their usual diet. Participants will receive dietary counseling from experienced nutritionists and eat a balanced diet (macronutrient distribution of approximately 10-15% protein, 55-65% carbohydrate and 20-30% fat).They are required to write daily dietary log. Besides, they are required to maintain their exercise routines and record their daily steps using a unified pedometer (Redmi Smart Band, Xiaomi Corporation, China). The use of drugs affecting blood glucose and LFC will be avoided.
Intervention Type
Behavioral
Intervention Name(s)
Continuous calorie restriction (CCR)
Other Intervention Name(s)
Daily calorie restriction
Intervention Description
Participants in CCR group were instructed to consume the prescribed calories (25 kcal / kg × [height (cm) - 100] kg) every day by eating conventional food without time restriction. Participants will receive dietary counseling from experienced nutritionists and eat a balanced diet (macronutrient distribution of approximately 10-15% protein, 55-65% carbohydrate and 20-30% fat).They are required to write daily dietary log. Besides, they are required to maintain their exercise routines and record their daily steps using a unified pedometer (Redmi Smart Band, Xiaomi Corporation, China). The use of drugs affecting blood glucose and LFC will be avoided.
Primary Outcome Measure Information:
Title
Change of liver fat content in %
Description
Change of liver fat content in %.
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Change of weight
Description
Change of weight in kilograms.
Time Frame
12 weeks
Title
Change of blood glucose: fasting blood glucose
Description
Change of fasting blood glucose in mmol/L.
Time Frame
12 weeks
Title
Change of blood glucose: 2h postload blood glucose
Description
Change of 2h postload blood glucose in mmol/L.
Time Frame
12 weeks
Title
Change of HbA1c
Description
Change of HbA1c in %.
Time Frame
12 weeks
Title
Change of liver enzymes: alanine aminotransferase
Description
Change of alanine aminotransferase in U/L.
Time Frame
12 weeks
Title
Change of liver enzymes: aspartate aminotransferase
Description
Change of aspartate aminotransferase in U/L.
Time Frame
12 weeks
Title
Change of liver enzymes: γ-glutamyl transpeptidase
Description
Change of γ-glutamyl transpeptidase in U/L.
Time Frame
12 weeks
Title
Change of lipid profile: total cholesterol
Description
Change of total cholesterol in mmol/L.
Time Frame
12 weeks
Title
Change of lipid profile: triglyceride
Description
Change of triglyceride in mmol/L.
Time Frame
12 weeks
Title
Change of lipid profile: high-density lipoprotein-cholesterol
Description
Change of high-density lipoprotein-cholesterol in mmol/L.
Time Frame
12 weeks
Title
Change of lipid profile: low-density lipoprotein-cholesterol
Description
Change of low-density lipoprotein-cholesterol in mmol/L.
Time Frame
12 weeks
Title
Change of lipid profile: free fatty acid
Description
Change of free fatty acid in mmol/L.
Time Frame
12 weeks
Other Pre-specified Outcome Measures:
Title
Change of fat mass
Description
measured by bioimpedance analyzer, fat mass in kilograms.
Time Frame
12 weeks
Title
Change of lean mass
Description
measured by bioimpedance analyzer, skeletal muscle mass in kilograms.
Time Frame
12 weeks
Title
Change of abdominal adiposity
Description
measured by MRI, including visceral adipose tissue and subcutaneous adipose tissue, all in square centimetres.
Time Frame
12 weeks
Title
Change of liver stiffness measure of liver transient elastography
Description
Change of liver stiffness measure of liver transient elastography, in kPa.
Time Frame
12 weeks
Title
Change of insulin sensitivity
Description
Change of HOMA-IR (fasting glucose in mmol/L x fasting insulin in μU/mL)/22.5).
Time Frame
12 weeks
Title
Change of fasting insulin
Description
Change of fasting insulin in μU/mL.
Time Frame
12 weeks
Title
Change of brain functional MRI
Description
Brain functional MRI will be used to evaluate the neural activity of the brain.
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria Age 18-70 Diagnosed as fatty liver by ultrasound or magnetic resonance imaging BMI ≥ 24 kg/m2 abnormal glucose metabolism: (meeting at least one): Impaired glucose regulation: fasting blood glucose ≥ 100 mg/dL, postprandial blood glucose ≥ 140 mg/dL or HbA1c ≥ 5.7% Diabetes mellitus: diabetic symptoms + plasma glucose concentration ≥ 200 mg/dL at any time or fasting plasma glucose concentration ≥ 100 mg/dL or OGTT 2 h plasma glucose concentration ≥ 200 mg/dL Exclusion Criteria Type 1 diabetes, gestational diabetes and other special types of diabetes Poor blood glucose control, HbA1c > 8.5% within 3 months Taking antidiabetic drugs in the past month Serum ALT > 6 times of normal upper limit Excessive alcohol consumption (alcohol intake: men > 140 g, women > 70 g in the past 6 months) Other liver diseases: such as acute and chronic viral hepatitis, drug-induced hepatitis, immune hepatitis, liver cirrhosis, liver cancer, etc Taking drugs that may affect MASLD in the past three months, such as vitamin E Biliary obstructive diseases Other diseases affecting glucose and lipid metabolism: hyperthyroidism, hypothyroidism, Cushing's syndrome, etc Chronic kidney disease (serum creatinine ≥ 2.0 mg/dL) Life expectancy of no more than 5 years Already pregnant or plan to be pregnant in the near future Mental illness Other conditions affecting follow-up Have participated in other clinical trials in the past 4 weeks Absent of informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hua Bian
Organizational Affiliation
Shanghai Zhongshan Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Xin Gao
Organizational Affiliation
Shanghai Zhongshan Hospital
Official's Role
Study Director
Facility Information:
Facility Name
Zhongshan Hospital, Fudan University
City
Shanghai
Country
China

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
26707365
Citation
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73-84. doi: 10.1002/hep.28431. Epub 2016 Feb 22.
Results Reference
background
PubMed Identifier
28642059
Citation
Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017 Oct;67(4):862-873. doi: 10.1016/j.jhep.2017.06.003. Epub 2017 Jun 19.
Results Reference
background
PubMed Identifier
23855290
Citation
Fan JG. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:11-7. doi: 10.1111/jgh.12036.
Results Reference
background
PubMed Identifier
25164003
Citation
Wang FS, Fan JG, Zhang Z, Gao B, Wang HY. The global burden of liver disease: the major impact of China. Hepatology. 2014 Dec;60(6):2099-108. doi: 10.1002/hep.27406. Epub 2014 Oct 29.
Results Reference
background
PubMed Identifier
11961152
Citation
Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002 Apr 18;346(16):1221-31. doi: 10.1056/NEJMra011775. No abstract available.
Results Reference
background
PubMed Identifier
26667191
Citation
Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, Roverato A, Guaraldi G, Lonardo A. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016 May;31(5):936-44. doi: 10.1111/jgh.13264.
Results Reference
background
PubMed Identifier
12031978
Citation
Vozarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, Bogardus C, Tataranni PA. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002 Jun;51(6):1889-95. doi: 10.2337/diabetes.51.6.1889.
Results Reference
background
PubMed Identifier
24002776
Citation
Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014 Mar;59(3):1174-97. doi: 10.1002/hep.26717. Epub 2014 Jan 16.
Results Reference
background
PubMed Identifier
25050550
Citation
Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, Hultcrantz R, Hagstrom H, Yoon SK, Charatcharoenwitthaya P, George J, Barrera F, Hafliethadottir S, Bjornsson ES, Armstrong MJ, Hopkins LJ, Gao X, Francque S, Verrijken A, Yilmaz Y, Lindor KD, Charlton M, Haring R, Lerch MM, Rettig R, Volzke H, Ryu S, Li G, Wong LL, Machado M, Cortez-Pinto H, Yasui K, Cassader M. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014 Jul 22;11(7):e1001680. doi: 10.1371/journal.pmed.1001680. eCollection 2014 Jul.
Results Reference
background
PubMed Identifier
15842581
Citation
Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J, Emick D, Lok AS, Conjeevaram HS. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol. 2005 May;100(5):1072-81. doi: 10.1111/j.1572-0241.2005.41334.x.
Results Reference
background
PubMed Identifier
30475966
Citation
Sundfor TM, Svendsen M, Tonstad S. Intermittent calorie restriction-a more effective approach to weight loss? Am J Clin Nutr. 2018 Nov 1;108(5):909-910. doi: 10.1093/ajcn/nqy288. No abstract available.
Results Reference
background
PubMed Identifier
28202779
Citation
Wei M, Brandhorst S, Shelehchi M, Mirzaei H, Cheng CW, Budniak J, Groshen S, Mack WJ, Guen E, Di Biase S, Cohen P, Morgan TE, Dorff T, Hong K, Michalsen A, Laviano A, Longo VD. Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. Sci Transl Med. 2017 Feb 15;9(377):eaai8700. doi: 10.1126/scitranslmed.aai8700.
Results Reference
background
PubMed Identifier
28235195
Citation
Cheng CW, Villani V, Buono R, Wei M, Kumar S, Yilmaz OH, Cohen P, Sneddon JB, Perin L, Longo VD. Fasting-Mimicking Diet Promotes Ngn3-Driven beta-Cell Regeneration to Reverse Diabetes. Cell. 2017 Feb 23;168(5):775-788.e12. doi: 10.1016/j.cell.2017.01.040.
Results Reference
background
PubMed Identifier
31375753
Citation
Johari MI, Yusoff K, Haron J, Nadarajan C, Ibrahim KN, Wong MS, Hafidz MIA, Chua BE, Hamid N, Arifin WN, Ma ZF, Lee YY. A Randomised Controlled Trial on the Effectiveness and Adherence of Modified Alternate-day Calorie Restriction in Improving Activity of Non-Alcoholic Fatty Liver Disease. Sci Rep. 2019 Aug 2;9(1):11232. doi: 10.1038/s41598-019-47763-8. Erratum In: Sci Rep. 2020 Jun 25;10(1):10599.
Results Reference
background
PubMed Identifier
30475957
Citation
Schubel R, Nattenmuller J, Sookthai D, Nonnenmacher T, Graf ME, Riedl L, Schlett CL, von Stackelberg O, Johnson T, Nabers D, Kirsten R, Kratz M, Kauczor HU, Ulrich CM, Kaaks R, Kuhn T. Effects of intermittent and continuous calorie restriction on body weight and metabolism over 50 wk: a randomized controlled trial. Am J Clin Nutr. 2018 Nov 1;108(5):933-945. doi: 10.1093/ajcn/nqy196.
Results Reference
background
PubMed Identifier
17425870
Citation
Liu M, Yan HM, Gao X, Gao J. [Association of abnormality of liver enzymes and metabolic syndrome in patients with nonalcoholic fatty liver disease]. Zhonghua Yi Xue Za Zhi. 2007 Jan 23;87(4):253-5. Chinese.
Results Reference
background

Learn more about this trial

Effect of Intermittent Calorie Restriction on MASLD Patients With Abnormal Glucose Metabolism

We'll reach out to this number within 24 hrs